During oral arguments last week, most of the justices seemed reluctant to roll back access to the drug. Instead, they focused on whether the plaintiffs had a legal right, or standing, to sue and questioned whether the doctors in the case, Food and Drug Administration v. Alliance for Hippocratic Medicine, had suffered any injury resulting from the agency’s actions….”